0 (0%)		01-14 09:37
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	1.8	1-year :	2
Resists	First :	1.54	Second :	1.72
Pivot price	1.44
Supports	First :	1.26	Second :	1.05
MAs	MA(5) :	1.38	MA(20) :	1.48
	MA(100) :	1.51	MA(250) :	1.46
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	13.2	D(3) :	17.9
RSI	RSI(14): 42.9
52-week	High :	2.41	Low :	1.02

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ATNM ] has closed above bottom band by 23.4%. Bollinger Bands are 35.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.36 - 1.36	1.36 - 1.37
Low:	1.28 - 1.29	1.29 - 1.3
Close:	1.34 - 1.35	1.35 - 1.36

Mon, 12 Jan 2026
After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum - Nasdaq

Mon, 22 Dec 2025
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance

Mon, 01 Dec 2025
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire

Mon, 17 Nov 2025
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile

Tue, 04 Nov 2025
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications - PR Newswire

Fri, 24 Oct 2025
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.